NRXP -MC $35 m - 2x Phase 3 results imminent expected during this month , a potential 10 bagger here with positive data readouts
upcoming milestones expected during Q2: Release of top-line data from its trial of NRX-101 in Treatment Resistant Suicidal Bipolar Depression Release of top-line data from Northwestern University's Department of Defense funded trial of the main component of NRX-101 in Chronic Pain NDA filing for IV Ketamine for treatment of Suicidal Depression
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.